Gene expression of cytochromes P450 in liver transplants over time

European Journal of Clinical Pharmacology

Volumn 60, Issue 6, 2004, Pages 413-420

  Thörn, Mari ^a,d   Lundgren, Stefan ^b   Herlenius, Gustaf ^b,c   Ericzon, Bo Göran ^b   Lööf, Lars ^d   Rane, Anders ^b  

^a CENTRAL HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytochrome P450; Drug metabolism; Liver transplantation

Indexed keywords

BETA ACTIN; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLYCOPROTEIN P; TACROLIMUS;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION;

ADULT; BILIRUBIN; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOENZYMES; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PROTHROMBIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TACROLIMUS; TIME FACTORS;

EID: 4544381899     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0786-4     Document Type: Article

References (45)

1. 450 superfamily. Pharmacol Ther 45:1-38
2. 450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42
3. 450 in humans. Trends Pharmacol Sci 10:107-109
4. 450. J Pharmacokinet Biopharm 24:461-473
5. Ueda K, Cornwell MM, Pastan I, Roninson IB, Ling V, Riordan JR (1986) The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 141:956-962
6. Watkins PB (1997) The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Delivery Rev 27:161-170
7. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T (1993) Human P-glycoprotein transports cyclosporine A and FK 506. J Biol Chem 268:6077-6080
8. Lo A, Burckkart GJ (1999) P-glycoprotein and drug therapy in organ transplantation. J Clin Pharmacol 39:995-1005
9. 450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134
10. 450phenotyping. J Pharmacol Exp Ther 296:351-358
11. Willingham MC, Cornwell MM, Cardarelli CO, Gottesman MM, Pastan I (1986) Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs. Cancer Res 46:5941-5946
12. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localisation of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84:7735-7738
13. Greiner B, Eichelbaum M, Fritz P, Kreichgauer H-P, Von Richter O, Zundler J, Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147-153
14. 450 3A4: Regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17
15. 450isoenzymes other than CYP 3A4. Drug Metab Dispos 22:811-813
16. Lemaire M, Fahr A and Maurer G (1990) Pharmacokinetics of cyclosporine: inter and intra-individual variations and metabolic pathways. Transplant Proc 22:1110-1112
17. Armstrong VW, Oellerich M (2000) New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem 34:9-16
18. Jain AB, Abu-Elmagd K, Abdallah H, Warty V, Fung J, Todo S, Starzl TE, Venkataramanan R (1993) Pharmacokinetics of FK506 in liver transplants recipients after continuous intravenous infusion. J Clin Pharmacol 33:606-611
19. Fukatsu S, Yano I, Igarishi T, Hashida T, Takayanagi K, Saito H, Uemoto S, Kiuchi T, Tanaka K, Inui K (2001) Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol 57:479-484
20. Levy GA (1999) Relationship of pharmacokinetics to clinical outcomes. Transplant Proc 31:1654-1658
21. 450 3A4-mRNA expression in a pig liver perfusion model. Clin Biochem 34:53-57
22. 450 isoforms in the rat kidney. Life Sci 60:143-149
23. Wu C-Y, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, Wacher VJ (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 58:492-497
24. Lown KS, Mayo RR, Leichtman AB, Hsaio H, Turgeon K, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB (1997) Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62:248-260
25. Sumida A, Kinoshita K, Fukada T, Matsuda H, Yamamoto I, Inaba T, Azuma J (1999) Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver. Biochem Biophys Res Commun 262:499-503
26. 450 mRNA expression in human liver and its relationship with enzyme activity. Arch Biochem Biophys 393:308-315
27. Kalayoglu M, Sollinger HW, Stratta RJ, D'Allesandro AM, Hoffman RM, Pirsch JD, Belzer FO (1988) Extended preservation of the liver for clinical transplantation. Lancet 19:617-619
28. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159
29. 450 gene expression in liver and blood in patients with suspected liver disease. Eur J Clin Pharmacol 57:403-409
30. Öhrvik J (2002) Nonparametric methods in the two-way layout. Chiang Mai J Sci 29:103-115
31. 450 in modulating cyclosporine levels in transplant patients. Transplant Proc 25:1980-1982
32. 450: interactions with Cya. Transplant Proc 23:2791-2793
33. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391
34. Jounaldi Y, Hyrailles V, Gervot L and Maurel P (1996) Detection of a CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein. Biochem Biophys Res Commun 221:466-470
35. 450 IIIA product that is differentially expressed in adult human liver. J Biol Chem 264:10388-10395
36. 450 III family. Mol Pharmacol 36:97-105
37. 450involved in drug metabolism. Crit Rev Toxicol 22:1-21
38. 450 IIIA5 (HLp3). Mol Pharmacol 38:207-213
39. 450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 28:781-788
40. 450 mRNA. Drug Metab Dispos 30:1108-1114
41. 450s: application to drug induction studies. Arch Biochem Biophys 376:109-116
42. Bader A, Hansen T, Kirchner G, Allmeling C, Haverich A, Borlak JT (2000) Primary porcine and hepatocyte cultures to study drug oxidation reactions. Br J Pharmacol 129:331-342
43. 450 mRNAs in patients with suspected liver diseases as assessed by reverse transcriptase-PCR. J Lab Clin Med 134:134-140
44. 450 mRNA molecules using competitive reverse transcriptase-PCR. DNA Cell Biol 17:231-238
45. Sy S, Ciaccia A, Li W, Roberts E, Okey A, Kalow W, Tang B-K (2002) Modeling of human hepatic CYP3A4 enzyme kinetics, protein and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression. Eur J Clin Pharmacol 58:357-365